Expanded Access Policy

At Vicore Pharma, our mission is to develop innovative and effective treatments for patients with serious diseases. We are committed to ensuring that our investigational medicines undergo rigorous scientific and clinical evaluation to establish their safety and efficacy before they become more widely available. Our goal is to provide access to our medicines at the appropriate time, once their benefits and risks are fully understood.

An investigational medicine is a drug that has not yet been approved by regulatory authorities for general use. Before an investigational medicine can be made available to patients outside of clinical trials, it must go through multiple phases of testing to ensure its safety, efficacy, and appropriate usage. These evaluations are conducted through carefully designed clinical trials that help us gather critical data to support regulatory approval and widespread availability.

Buloxibutid (C21) is currently being investigated in a Phase 2b clinical trial, with its benefit-risk profile still being defined through ongoing clinical research and development. Until we have completed the necessary evaluations to determine the full impact of the medicine, we are unable to provide it outside of a research setting.

We remain dedicated to developing promising new medications that address unmet medical needs through structured research. As we continue our research, we will reassess our policies and provide updates when appropriate.